BCL2 and cancer: These findings suggest that MCL1 inhibition should be fine-tuned and that the relative contribution of BCL-2-family components to the apoptosis resistance of cancer cells should be carefully evaluated through the “BH3 profiling” to determine the therapeutic window [248, 249].